Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
Merkel Cell Carcinoma|Neuroendocrine Carcinoma of the Skin|Trabecular Carcinoma of the Skin
DRUG: Lenvatinib Oral Product|DRUG: Pembrolizumab
Pathological Complete Response, Pathological Complete Response will be determined by pathologist examination of tissue after neoadjuvant treatment and resection, 1 year
Progression Free Survival, Progressive disease will be defined by the detection of any recurrent disease following complete surgical resection or by progression of disease that is not amenable to complete surgical resection prior to planned surgery., 1 year|Percentage of patients able to complete both neoadjuvant cycles of trial therapy and able to complete planned surgical resection., Feasibility of treatment will be defined by the percentage of patients able to complete both neoadjuvant cycles of trial therapy and be able to complete surgical resection as planned., 1 year
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.